top of page
Eradicus

Molecular Diagnostic
Solutions For Pathogen Management

Eradicus is a biotechnology company that specialises in molecular biology chemistries for the purposes of developing in-vitro testing solutions intended for surveillance and diagnosis of infectious pathogens.

Namaskar.

Bienvenue.
Welcome.

We were founded in 2019 with the mission of facilitating affordable access to molecular diagnostic technologies across a wide range of applications including human health, animal health, food bio-security, and environmental monitoring. 

 

We now have a firmly rooted presence in India and France. Our centre of excellence in Haryana, India serves as our exclusive global manufacturing hub of our in-vitro diagnostics assays. While our innovation centre in Provence, France supports our applied research programs.

We have built a diverse and comprehensive IVD Design pipeline.

​We have a diverse R&D portfolio that includes in-vitro diagnostic assays covering over 100 infectious pathogens based on both conventional RT-PCR and next-generation molecular detection chemistries.

​

Our research and product development is prioritised on delivering highly impactful solutions to our partners in the private and public sectors.​​

We work in a mission oriented manner.

At Eradicus, we believe that our talent and resources are best utilised when we work in a mission oriented manner, wherein our interventions yield a transformational change within a given application use case.


We develop a combination of wet-chemistry, instrumentation, and IT applications that come together to provide a comprehensive solution.

Mission 01: COVID-19 Emergency

Our molecular testing solutions made testing accessible in lower income settings, and helped save over a billion dollars in healthcare expenditure for our public sector partners.

Status: Sucessfully Completed 

Mission 02: Hepatitis B Virus

We are enhancing access to Hepatitis B Virus molecular testing in low income settings in India.

Status: Active Field Deployment (2025)

Mission 03: TB Eradication

We are striving to make our next-generation molecular diagnostic solution for 'Tuberculosis' disruptively accessible to over 1 billion Indians.

Mission Status: Launch in Q2 2025 

bottom of page